05:03 AM EST, 12/10/2024 (MT Newswires) -- Recursion Pharmaceuticals ( RXRX ) said late Monday that an ongoing phase 1/2 clinical study of its drug REC-617 as a potential monotherapy for the treatment of advanced solid tumors was generally well-tolerated across all dose levels.

The company said that a "confirmed durable partial response" was achieved in one of the 18 evaluable patients in the study with metastatic, platinum-resistant ovarian cancer receiving REC-617 monotherapy.

Four of the patients achieved a "best response of stable disease" in multiple dose levels for up to six months of treatment, the company said.

Recursion plans to launch the next phase of the study and initiate REC-617 combination studies next year.